Quest Diagnostics integrates oncology testing into Flatiron OncoEMR via pilot with American Oncology Network
Quest Diagnostics Incorporated DGX | 0.00 | |
American Oncology Network, Inc. - Class A Common Stock AONC | 0.00 |
- Quest Diagnostics launched a pilot with Flatiron Health to integrate Haystack MRD and genomic profiling test ordering into the OncoEMR EHR.
- American Oncology Network joined the pilot; nearly 200 sites can order tests through the opt-in OncoEMR Molecular Profiling Integration feature.
- Full rollout is targeted for the second half of 2026; integration would reach 4,700 clinicians across 1,600 community oncology locations.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607080852PR_NEWS_USPR_____NY98768) on July 08, 2026, and is solely responsible for the information contained therein.